Assistant Researcher:Dai Wenbing_

Wenbing Dai, PhD, Assistant Researcher

Tel/Fax：010-82805724

Got his bachelor degree from Department of Pharmaceutics, College of Pharmacy, Wuhan University in 2003; Got his master degree from Department of Pharmaceutics, College of Pharmacy, Wuhan University in 2006；Got his doctor degree from Department of Pharmaceutics, School of Pharmaceutical Science, Peking University in 2009；Engaged in his postdoctoral fellow in School of Basic Medical Sciences, Peking University from 2009 to 2012; Has been working in Department of Pharmaceutics, School of Pharmaceutical Science, Peking University since 2012.

He has taken part in several research programs, the on-going programs including the National Basic Research Program (973 Program). He has published about ten articles and applied five patents.

Research Interesting：

Tumor targeting drug delivery system；Nanotechnology to improve the oral bioavailability of poor soluble drugs；Research and Development of Novel delivery systems；

Publications：

1.Dai W, Yang T, Wang Y, Wang X, Wang J, Zhang X, Zhang Q*. PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells. J drug target, 2010, 18: 254.

2.Dai W, Yang T, Wang Y, Wang X, Wang J, Zhang X, Zhang Q*.Peptide PHSCNK as an integrin α5β1 antagonist targets stealth liposomes to integrin-overexpressing melanoma. Nanomedicine: NMB, 2012, 8(7):1152-61.

3.He S, Cui Z, Mei D, Zhang H, Wang X, Dai W*, Zhang Q. A Cremophor-free self-microemulsified delivery system for intravenous injection of teniposide: evaluation in vitro and in vivo. AAPS PharmSciTech. 2012, 13(3):846-52.

4.Dai W, Jin W, Zhang J, Wang X, Wang J, Zhang X, Wan Y, Zhang Q. Spatiotemporally Controlled Co-delivery of Anti-vasculature Agent and Cytotoxic Drug by Octreotide-Modified Stealth Liposomes. Pharm Res. 2012, 29(10):2902-11.

5.Zhao S, Dai W, He B, Wang J, He Z, Zhang X, Zhang Q*. Monitoring the transport of polymeric micelles across MDCK cell monolayer and exploring related mechanisms. J Control Release, 2012, 160(3): 413-23

6.Zheng N, Dai W, Du W, Zhang H, Lei L, Zhang H, Wang X, Wang J, Zhang X, Gao J, Zhang Q*. A Novel Lanreotide-Encoded Micelle System Targets Paclitaxel to the Tumors with Overexpression of Somatostatin Receptors. Mol. Pharmaceutics, 2012, 9:1175.

7.Liang L, Lin S, Dai W, Lu J, Yang T, Xiang Y, Zhang Y, Li R, Zhang Q*. Novel cathepsin B-sensitive paclitaxel conjugate: higher water solubility, better efficacy and lower toxicity. J Control Release. 2012, 3:618-29

8.Yang T, Wang Y, Li Z, Dai W, Yin J, Liang L, Ying X, Zhou S, Wang J, Zhang X, Zhang Q*.Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine: NMB, 2012, 8:81-92.